AI Doesn’t Ask Why — But Physicians And Drug Developers Want To Know

Healthcare Guys

At long last, we seem to be on the threshold of departing the earliest phases of AI, defined by the always tedious “will AI replace doctors/drug developers/occupation X?” By DAVID SHAYWITZ MD.

BenevolentAI gets $115M to harness AI for new drug discovery

Mobi Health News

BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States.

MedTech’s Role in Fighting the Opioid Epidemic

Duane Boise

Of the 50,000 drug overdose deaths that occurred in 2015, roughly 33,000 of them were caused by opioids. More forms of technology are being developed every day to treat patients suffering from chronic pain, and to remedy those that may be struggling with an opioid addiction.

Cost of antibiotic-resistant infections in U.S. tops $2B per year

FierceHealthIT

The study’s authors urge policymakers to support the development of new strategies to prevent infections and to support innovative antibiotic drug development A new study finds that antibiotic resistance adds more than $1,000 to the cost of treatment for a single patient. Multiply that by the estimated number of antibiotic-resistant infections, and costs run well over $2 billion per year.

The Fourth Wave: Digital Health Newsletter — Nov 14, 2018 — No. 112

Story of Digital Health

From drug developers all the way to providers, it’s key to find secure ways to access and use data to improve human health, all while protecting individuals’ privacy. From drug developers all the. The Fourth Wave: Digital Health Newsletter — Nov 13, 2018 — No.

The Fourth Wave: Digital Health Newsletter — Nov 9, 2018 — No. 111

Story of Digital Health

However, the agency states that the new test by 23andMe can’t assess whether a drug is appropriate or be considered by users to be medical advice. RESEARCH & DRUG DEVELOPMENt. The Fourth Wave: Digital Health Newsletter — Nov 6, 2018 — No.

Leveraging T2D Drugs to improve T1D Therapy

Insulin Nation

In his studies, Type 1 diabetic patients have significantly benefited when their daily insulin regimen is supplemented with drugs developed to treat Type 2 diabetes. This was the first research ( release ) on using this Type 2 approved drug for T1D treatment and there were larger confirmatory studies ( release ) in 2016 and 2018. The study will supplement insulin therapy with these two drugs designed to treat Type 2 Diabetes or with semaglutide alone. “

Novartis CEO Is Going All in With Some Big Bets on R&D

Lloyd Price

In an interview with the Wall Street Journal, Narasimhan pointed to some of the investments the company has made into the cutting-edge areas of drug development, such as gene therapy and radiopharmaceuticals.

Blockchain: Its Future in Healthcare is Happening Now

HitPoint Blog

For physicians, this would enable customized individual treatment plans co-developed by a patient’s various caregivers, based on full histories, patient genetics, lifecycle and environment. Interoperability. Blockchain.

Genomics Startup Human Longevity’s Valuation Falls 80% from $1.6 Billion down to $310M

Lloyd Price

But key facets of its business didn’t develop as planned, say people familiar with the company. It had hoped to sell analytics to pharmaceutical companies as they increasingly incorporated genetic sequencing into drug development, these people say. Human Longevity Inc.

Lilly Acquires Rights to Nasal Glucagon

Insulin Nation

has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline.

The Fourth Wave: Digital Health Update ? Paul Sonnier ? July 20, 2018 ? #335

Story of Digital Health

The company uses AI to speed up the drug development process and has a particular focus on therapies for Parkinsons and ALS, which it plans to test in humans several years from now. I made this announcement to 63,919 members of the Digital Health group on LinkedIn.

FemTech: The rise of Female Health innovation

Lloyd Price

CVC’s recent acquisition of the women’s health division of the Israeli drug developer Teva for $800m created a company dedicated to contraception, fertility, menopause and osteoporosis. Silicon Valley Bank, Zinc.vc

Donald Trump and Diabetes Policy: What We Know Right Now

Insulin Nation

Within a bullet point about Obamacare is this sentence: “Reforms will also include cutting the red tape at the FDA: there are over 4,000 drugs awaiting approval, and we especially want to speed the approval of life-saving medications.”.

How the 21st Century Cures Act Will Change Diabetes Care

Insulin Nation

This legislation boosts funding to the National Institutes of Health and establishes an innovation grant fund to “accelerate the discovery, development, and delivery” of new treatments and therapies. She also said the bill opened the door to easy off-label use of FDA-cleared drugs. “I

Lilly Acquires Rights to Nasal Glucagon

Insulin Nation

has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline.

The Fourth Wave: Digital Health Update ? Paul Sonnier ? Sep 11, 2018 ? #342

Story of Digital Health

Auckland University of Technology researchers have developed a first-of-its-kind artificial intelligence “spiking neural networks” machine learning system that obtains brain data from EEG headsets and can then predict a person’s choices 0.2

What is Metformin?

Insulin Nation

A drug prescription can come with a lot of questions. With our “Know Your Drugs” series, we provide you with a snapshot of the different diabetes drugs on the market, and links to additional information.

Join us at the Global Clinical Trials Connect 2018, 25-26 April, London

mHealth Insight

“The Global Clinical Trials Connect 2018 conference focuses on introducing pioneer technology, developing better patient engagement and collaborating strategies in clinical trials. Aji Barot, Business Development Director, HealthUnlocked.

The Fourth Wave: Digital Health Update ? Paul Sonnier ? Apr 24, 2018 ? #323

Story of Digital Health

While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.” ” As I point out in my book, drug development could involve a model of direct government funding and licensing.

New Blockchain ledger will let US residents sell personal Healthcare data

Lloyd Price

Most people don't know it but there is a multi-billion dollar industry that collects healthcare information, strips it of basic personal identifiers such as name, address and Social Security Number, and then sells it off to researchers, drug developers, marketers and others.

Lilly Acquires Rights to Nasal Glucagon

Insulin Nation

has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline.

The Fourth Wave: Digital Health Update ? Paul Sonnier ? Jan 15, 2018 ? #309

Story of Digital Health

It’s hoped that by identifying symptoms as they are developing and before they manifest completely treatment can begin earlier. In the UK, six drug companies will decode the genes of 500,000 Brits and make the data public by 2020 via the UK Biobank.

The Fourth Wave: Digital Health Update ? Paul Sonnier ? May 9, 2018 ? #325

Story of Digital Health

” During F8, Facebook’s annual developer conference, CEO Mark Zuckerberg announced the launch of a new dating service. I made this announcement to 62,782 members of the Digital Health group on LinkedIn.

The Fourth Wave: Digital Health Update ? Paul Sonnier ? Apr 10, 2018 ? #321

Story of Digital Health

” Coinicidentally, while attending an event at the Salk Institute here in San Diego today, someone said pretty much the same thing to me regarding traditional versus digital-enabled modern drug development: “we can’t go back.”

FDA Gives Diabetes Treatments Low Priority

Insulin Nation

DiMasi, PhD, who analyzes the economics of health care at the Tufts University Center for the Study of Drug Development. We’ve seen very large trials and lengthening clinical development times, which would suggest larger than average development costs,” DiMasi said.